- Home
- GYRE vs GHRS Comparison
GYRE vs GHRS Comparison
Compare GYRE & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- GHRS
- Stock Information
- Founded
- GYRE 2002
- GHRS 2018
- Country
- GYRE United States
- GHRS Ireland
- Employees
- GYRE N/A
- GHRS 50
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- GYRE Health Care
- GHRS Health Care
- Exchange
- GYRE Nasdaq
- GHRS Nasdaq
- Market Cap
- GYRE 755.7M
- GHRS 839.9M
- IPO Year
- GYRE N/A
- GHRS 2021
- Fundamental
- Price
- GYRE $8.19
- GHRS $15.07
- Analyst Decision
- GYRE Strong Buy
- GHRS Strong Buy
- Analyst Count
- GYRE 2
- GHRS 10
- Target Price
- GYRE $17.00
- GHRS $29.90
- AVG Volume (30 Days)
- GYRE 60.0K
- GHRS 320.9K
- Earning Date
- GYRE 11-07-2025
- GHRS 11-06-2025
- Dividend Yield
- GYRE N/A
- GHRS N/A
- EPS Growth
- GYRE N/A
- GHRS N/A
- EPS
- GYRE 0.04
- GHRS N/A
- Revenue
- GYRE $107,265,000.00
- GHRS N/A
- Revenue This Year
- GYRE $15.25
- GHRS N/A
- Revenue Next Year
- GYRE $33.14
- GHRS N/A
- P/E Ratio
- GYRE $211.54
- GHRS N/A
- Revenue Growth
- GYRE 2.13
- GHRS N/A
- 52 Week Low
- GYRE $6.11
- GHRS $6.72
- 52 Week High
- GYRE $19.00
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- GYRE 59.01
- GHRS 60.90
- Support Level
- GYRE $7.12
- GHRS $12.45
- Resistance Level
- GYRE $7.42
- GHRS $13.89
- Average True Range (ATR)
- GYRE 0.34
- GHRS 0.95
- MACD
- GYRE 0.04
- GHRS 0.11
- Stochastic Oscillator
- GYRE 94.82
- GHRS 90.58
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.